ERK and PI3K regulate different aspects of the epithelial to mesenchymal transition of mammary tumor cells induced by truncated MUC1

Experimental Cell Research

Volumn 315, Issue 8, 2009, Pages 1490-1504

  Horn, Galit ^a   Gaziel, Avital ^a   Wreschner, Daniel H ^a,b   Smorodinsky, Nechama I ^a   Ehrlich, Marcelo ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b Biomodifying LLC   (United States)

Author keywords

Breast cancer; EMT; ERK; Mammary tumor; MUC1; PI3K

Indexed keywords

ALPHA5 INTEGRIN; CELL MARKER; FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SP1; UVOMORULIN; VIMENTIN;

ANIMAL CELL; ARTICLE; BREAST TUMOR; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; EPITHELIUM CELL; GENETIC TRANSFECTION; GENOMIC FRAGMENT; HUMAN; HUMAN CELL; MESENCHYME CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

EID: 64049093492     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2009.02.011     Document Type: Article

References (65)

1. Lee J.M., Dedhar S., Kalluri R., and Thompson E.W. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol. 172 (2006) 973-981
2. Thiery J.P. Epithelial-mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol. 15 (2003) 740-746
3. Yang J., and Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 14 (2008) 818-829
4. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214 (2008) 199-210
5. Kang Y., and Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118 (2004) 277-279
6. Peinado H., Olmeda D., and Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat. Rev. Cancer 7 (2007) 415-428
7. Larue L., and Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 24 (2005) 7443-7454
8. Huber M.A., Kraut N., and Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 17 (2005) 548-558
9. Keydar I., Chou C.S., Hareuveni M., Tsarfaty I., Sahar E., Selzer G., Chaitchik S., and Hizi A. Production and characterization of monoclonal antibodies identifying breast tumor-associated antigens. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 1362-1366
10. Heukamp L.C., van Hall T., Ossendorp F., Burchell J.M., Melief C.J., Taylor-Papadimitriou J., and Offringa R. Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope. J. Immunother. 25 (2002) 46-56
11. Levitin F., Stern O., Weiss M., Gil-Henn C., Ziv R., Prokocimer Z., Smorodinsky N.I., Rubinstein D.B., and Wreschner D.H. The MUC1 SEA module is a self-cleaved domain. J. Biol. Chem. 280 (2005) 33374-33386
12. Macao B., Johansson D.G., Hansson G.C., and Hard T. Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucin. Nat. Struct. Mol. Biol. 13 (2006) 71-76
13. Ligtenberg M.J., Kruijshaar L., Buijs F., van Meijer M., Litvinov S.V., and Hilkens J. Cell-associated episialin is a complex containing two proteins derived from a common precursor. J. Biol. Chem. 267 (1992) 6171-6177
14. Carraway III K.L., Funes M., Workman H.C., and Sweeney C. Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. Curr. Top. Dev. Biol. 78 (2007) 1-22
15. Carson D.D. The cytoplasmic tail of MUC1: a very busy place. Science signaling 1 (2008) pe35
16. Huang L., Ren J., Chen D., Li Y., Kharbanda S., and Kufe D. MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation. Cancer Biol. Ther. 2 (2003) 702-706
17. Li Q., Ren J., and Kufe D. Interaction of human MUC1 and beta-catenin is regulated by Lck and ZAP-70 in activated Jurkat T cells. Biochem. Biophys. Res. Commun. 315 (2004) 471-476
18. Singh P.K., and Hollingsworth M.A. Cell surface-associated mucins in signal transduction. Trends Cell Biol. 16 (2006) 467-476
19. Gendler S.J. MUC1, the renaissance molecule. J. Mammary Gland Biol. Neoplasia 6 (2001) 339-353
20. Wreschner D.H., Zrihan-Licht S., Baruch A., Sagiv D., Hartman M.L., Smorodinsky N., and Keydar I. Does a novel form of the breast cancer marker protein, MUC1, act as a receptor molecule that modulates signal transduction?. Adv. Exp. Med. Biol. 353 (1994) 17-26
21. Baba T., Udaka K., Terada N., Ueda H., Fujii Y., Ohno S., and Sato S.B. Actin-rich spherical extrusion induced in okadaic acid-treated K562 cells by crosslinking of membrane microdomains. J. Histochem. Cytochem. 51 (2003) 245-252
22. Hattrup C.L., and Gendler S.J. MUC1 alters oncogenic events and transcription in human breast cancer cells. Breast Cancer Res. 8 (2006) R37
23. Ramasamy S., Duraisamy S., Barbashov S., Kawano T., Kharbanda S., and Kufe D. The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol. Cell 27 (2007) 992-1004
24. Rubinstein D.B., Karmely M., Ziv R., Benhar I., Leitner O., Baron S., Katz B.Z., and Wreschner D.H. MUC1/X protein immunization enhances cDNA immunization in generating anti-MUC1 alpha/beta junction antibodies that target malignant cells. Cancer Res. 66 (2006) 11247-11253
25. Smorodinsky N., Weiss M., Hartmann M.L., Baruch A., Harness E., Yaakobovitz M., Keydar I., and Wreschner D.H. Detection of a secreted MUC1/SEC protein by MUC1 isoform specific monoclonal antibodies. Biochem. Biophys. Res. Commun. 228 (1996) 115-121
26. Fu Y.X., Watson G., Jimenez J.J., Wang Y., and Lopez D.M. Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor. Cancer Res. 50 (1990) 227-234
27. Baruch A., Hartmann M., Zrihan-Licht S., Greenstein S., Burstein M., Keydar I., Weiss M., Smorodinsky N., and Wreschner D.H. Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function. Int. J. Cancer 71 (1997) 741-749
28. Herbert L.M., Grosso J.F., Dorsey Jr. M., Fu T., Keydar I., Cejas M.A., Wreschner D.H., Smorodinski N., and Lopez D.M. A unique mucin immunoenhancing peptide with antitumor properties. Cancer Res. 64 (2004) 8077-8084
29. Baruch A., Hartmann M., Yoeli M., Adereth Y., Greenstein S., Stadler Y., Skornik Y., Zaretsky J., Smorodinsky N.I., Keydar I., and Wreschner D.H. The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein. Cancer Res. 59 (1999) 1552-1561
30. Grosso J.F., Herbert L.M., Owen J.L., and Lopez D.M. MUC1/sec-expressing tumors are rejected in vivo by a T cell-dependent mechanism and secrete high levels of CCL2. J. Immunol. 173 (2004) 1721-1730
31. Ilkovitch D., Handel-Fernandez M.E., Herbert L.M., and Lopez D.M. Antitumor effects of Mucin 1/sec involves the modulation of urokinase-type plasminogen activator and signal transducer and activator of transcription 1 expression in tumor cells. Cancer Res. 68 (2008) 2427-2435
32. Hinojosa-Kurtzberg A.M., Johansson M.E., Madsen C.S., Hansson G.C., and Gendler S.J. Novel MUC1 splice variants contribute to mucin overexpression in CFTR-deficient mice. Am. J. Physiol. Gastrointest Liver Physiol. 284 (2003) G853-862
33. Mukherjee P., Ginardi A.R., Tinder T.L., Sterner C.J., and Gendler S.J. MUC1-specific cytotoxic T lymphocytes eradicate tumors when adoptively transferred in vivo. Clin. Cancer Res. 7 (2001) 848s-855s
34. Jungert K., Buck A., von Wichert G., Adler G., Konig A., Buchholz M., Gress T.M., and Ellenrieder V. Sp1 is required for transforming growth factor-beta-induced mesenchymal transition and migration in pancreatic cancer cells. Cancer Res. 67 (2007) 1563-1570
35. Sarrio D., Rodriguez-Pinilla S.M., Hardisson D., Cano A., Moreno-Bueno G., and Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 68 (2008) 989-997
36. Lee M.Y., Chou C.Y., Tang M.J., and Shen M.R. Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation. Clin. Cancer Res. 14 (2008) 4743-4750
37. Hudson M.J., Stamp G.W., Hollingsworth M.A., Pignatelli M., and Lalani E.N. MUC1 expressed in PanC1 cells decreases adhesion to type 1 collagen but increases contraction in collagen lattices. Am. J. Pathol. 148 (1996) 951-960
38. Wesseling J., van der Valk S.W., Vos H.L., Sonnenberg A., and Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J. Cell Biol. 129 (1995) 255-265
39. Wykes M., MacDonald K.P., Tran M., Quin R.J., Xing P.X., Gendler S.J., Hart D.N., and McGuckin M.A. MUC1 epithelial mucin (CD227) is expressed by activated dendritic cells. J. Leukoc. Biol. 72 (2002) 692-701
40. Hattrup C.L., and Gendler S.J. Structure and function of the cell surface (tethered) mucins. Annu. Rev. Physiol. 70 (2008) 431-457
41. Orlichenko L.S., and Radisky D.C. Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin. Exp. Metastasis 25 (2008) 593-600
42. Ellenrieder V., Hendler S.F., Boeck W., Seufferlein T., Menke A., Ruhland C., Adler G., and Gress T.M. Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res. 61 (2001) 4222-4228
43. Javle M.M., Gibbs J.F., Iwata K.K., Pak Y., Rutledge P., Yu J., Black J.D., Tan D., and Khoury T. Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann. Surg. Oncol. 14 (2007) 3527-3533
44. Irie H.Y., Pearline R.V., Grueneberg D., Hsia M., Ravichandran P., Kothari N., Natesan S., and Brugge J.S. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J. Cell Biol. 171 (2005) 1023-1034
45. Xie L., Law B.K., Chytil A.M., Brown K.A., Aakre M.E., and Moses H.L. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia 6 (2004) 603-610
46. Cho H.J., Baek K.E., Saika S., Jeong M.J., and Yoo J. Snail is required for transforming growth factor-beta-induced epithelial-mesenchymal transition by activating PI3 kinase/Akt signal pathway. Biochem. Biophys. Res. Commun. 353 (2007) 337-343
47. Blick T., Widodo E., Hugo H., Waltham M., Lenburg M.E., Neve R.M., and Thompson E.W. Epithelial mesenchymal transition traits in human breast cancer cell lines. Clin. Exp. Metastasis 25 (2008) 629-642
48. Zajchowski D.A., Bartholdi M.F., Gong Y., Webster L., Liu H.L., Munishkin A., Beauheim C., Harvey S., Ethier S.P., and Johnson P.H. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res. 61 (2001) 5168-5178
49. Li Q., and Mattingly R.R. Restoration of E-cadherin cell-cell junctions requires both expression of E-cadherin and suppression of ERK MAP kinase activation in Ras-transformed breast epithelial cells. Neoplasia 10 (2008) 1444-1458
50. Cailleau R., Olive M., and Cruciger Q.V. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 14 (1978) 911-915
51. Cailleau R., Young R., Olive M., and Reeves Jr. W.J. Breast tumor cell lines from pleural effusions. J. Natl. Cancer Inst. 53 (1974) 661-674
52. Keydar I., Chen L., Karby S., Weiss F.R., Delarea J., Radu M., Chaitcik S., and Brenner H.J. Establishment and characterization of a cell line of human breast carcinoma origin. Eur. J. Cancer 15 (1979) 659-670
53. Lakka S.S., Jasti S.L., Gondi C., Boyd D., Chandrasekar N., Dinh D.H., Olivero W.C., Gujrati M., and Rao J.S. Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene 21 (2002) 5601-5608
54. Viala E., and Pouyssegur J. Regulation of tumor cell motility by ERK mitogen-activated protein kinases. Ann. N. Y. Acad. Sci. 1030 (2004) 208-218
55. Batlle E., Sancho E., Franci C., Dominguez D., Monfar M., Baulida J., and Garcia De Herreros A. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2 (2000) 84-89
56. Cano A., Perez-Moreno M.A., Rodrigo I., Locascio A., Blanco M.J., del Barrio M.G., Portillo F., and Nieto M.A. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2 (2000) 76-83
57. Eger A., Aigner K., Sonderegger S., Dampier B., Oehler S., Schreiber M., Berx G., Cano A., Beug H., and Foisner R. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 24 (2005) 2375-2385
58. Thompson E.J., Shanmugam K., Hattrup C.L., Kotlarczyk K.L., Gutierrez A., Bradley J.M., Mukherjee P., and Gendler S.J. Tyrosines in the MUC1 cytoplasmic tail modulate transcription via the extracellular signal-regulated kinase 1/2 and nuclear factor-kappaB pathways. Mol. Cancer Res. 4 (2006) 489-497
59. Gion M., Mione R., Leon A.E., Luftner D., Molina R., Possinger K., and Robertson J.F. CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur. J. Cancer 37 (2001) 355-363
60. Creaney J., Segal A., Sterrett G., Platten M.A., Baker E., Murch A.R., Nowak A.K., Robinson B.W., and Millward M.J. Overexpression and altered glycosylation of MUC1 in malignant mesothelioma. Br. J. Cancer 98 (2008) 1562-1569
61. Rughetti A., Pellicciotta I., Biffoni M., Backstrom M., Link T., Bennet E.P., Clausen H., Noll T., Hansson G.C., Burchell J.M., Frati L., Taylor-Papadimitriou J., and Nuti M. Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. J. Immunol. 174 (2005) 7764-7772
62. Liu X., Yan S., Zhou T., Terada Y., and Erikson R.L. The MAP kinase pathway is required for entry into mitosis and cell survival. Oncogene 23 (2004) 763-776
63. Shaul Y.D., and Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim. Biophys. Acta 1773 (2007) 1213-1226
64. Vantaggiato C., Formentini I., Bondanza A., Bonini C., Naldini L., and Brambilla R. ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. J. Biol. 5 (2006) 14
65. Bourcier C., Jacquel A., Hess J., Peyrottes I., Angel P., Hofman P., Auberger P., Pouyssegur J., and Pages G. p44 mitogen-activated protein kinase (extracellular signal-regulated kinase 1)-dependent signaling contributes to epithelial skin carcinogenesis. Cancer Res. 66 (2006) 2700-2707